
ASSOCIATION OF E-SELECTIN S128R POLYMORPHISM
WITH HEREDITARY BREAST CARCINOMA
SUSCEPTIBILITY IN TURKISH PATIENTS
WITHOUT BRCA1/2 GERMLINE MUTATIONS Yararbas K, Atalay PB *Corresponding Author: Kanay Yararbas, M.D., Assistant Professor, Department of Medical Genetics, Acibadem Mehmet
Ali Aydinlar University Faculty of Medicine; İçerenköy Mahallesi, Kayisdagi Caddesi, No: 32, 34742, Istanbul, Turkey.
Tel: +90-216-500-4785. Fax: +90-216-500-5076. E-mail: kanay.yararbas@ acibadem.edu.tr page: 27
|
REFERENCES
1. Public Health Agency of Turkey, Department
of Cancer, Cancer Registry in Turkey. Available
from: http:// kanser.gov.tr/daire-faaliyetleri/kanserkayitciligi/
108-türkiyede-kanser-kayitcigi.html.
2. McPherson K, Steel CM, Dixon JM. ABC of breast
diseases. Breast cancer-epidemiology, risk factors,
and genetics. BMJ. 2000; 321(7261): 624-628.
3. Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-
Associated Hereditary Breast and Ovarian Cancer,
1998 [updated 2016]. In: Adam MP, Ardinger HH,
Pagan RA, Wallace SE, Amemiya A, Bean LJH, et al.,
Eds. GeneReviews® [Internet]. Seattle (WA, USA):
University of Washington, Seattle, WA, USA. (https://
www.ncbi.nlm. nih.gov/pubmed/20301425.)
4. Ford D, Easton DF, Stratton M, Narod S, Goldgar D,
Devilee P, et al. Genetic heterogeneity and penetrance
analysis of the BRCA1 and BRCA2 genes in breast
cancer families. The Breast Cancer Linkage Consortium.
Am J Hum Genet. 1998; 62(3): 676-689.
5. Easton DF, Ford D, Bishop DT. Breast and ovarian
cancer incidence in BRCA1-mutation carriers. Breast
Cancer Linkage Consortium. Am J Hum Genet. 1995;
56(1): 265-271.
6. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord
JE, Hopper JL, et al. Average risks of breast and
ovarian cancer associated with BRCA1 or BRCA2
mutations detected in case series unselected for family
history: A combined analysis of 22 studies. Am J
Hum Genet. 2003; 72(5): 1117-1130.
7. Smith A, Moran A, Boyd MC, Bulman M, Shenton A,
Smith L, et al. Phenocopies in BRCA1 and BRCA2
families: Evidence for modifier genes and implications
for screening. J Med Genet. 2007; 44(1): 10-15.
8. L aubli H, Borsig L. Selectins promote tumor metastasis.
Semin Cancer Biol. 2010; 20(3): 169-177.
9. L ey K. The role of selectins in inflammation and
disease. Trends Mol Med. 2003; 9(6): 263-268.
10. Krause T, Turner GA. Are selectins involved in metastasis?
Clin Exp Metastasis. 1999; 17(3): 183-192.
11. Khatib AM, Fallavollita L, Wancewicz EV, Monia BP,
Brodt P. Inhibition of hepatic endothelial E-selectin
expression by C-raf antisense oligonucleotides blocks
colorectal carcinoma liver metastasis. Cancer Res.
2002; 62(19): 5393-5398.
12. L aferriere J, Houle F, Taher MM, Valerie K, Huot J.
Transendothelial migration of colon carcinoma cells
requires expression of E-selectin by endothelial cells
and activation of stress-activated protein kinase-2
(SAPK2/ p38) in the tumor cells. J Biol Chem. 2001;
276(36): 33762-33772.
13. Bal N, Kocer NE, Ertorer ME, Canpolat ET, Kayaselcuk
F. Maspin, E-selectin, and P-selectin expressions
in papillary thyroid carcinomas and their correlation
with prognostic parameters. Pathol Res Pract. 2008;
204(10): 743-750.
14. Banks RE, Gearing AJ, Hemingway IK, Norfolk DR,
Perren TJ, Selby PJ. Circulating intercellular adhesion
molecule-1 (ICAM-1), E-selectin and vascular cell
adhesion molecule-1 (VCAM-1) in human malignancies.
Br J Cancer. 1993; 68(1): 122-124.
15. Dymicka-Piekarska V, Kemona H. Does colorectal
cancer clinical advancement affect adhesion molecules
(sP-selectin, sE-selectin and ICAM-1) concentration?
Thromb Res. 2009; 124(1): 80-83.
16. Ke JJ, Shao QS, Ling ZQ. Expression of E-selectin,
integrin β1 and immunoglobulin superfamily member
in human gastric carcinoma cells and its clinicopathologic
significance. World J Gastroenterol. 2006;
12(22): 3609-3611.
17. Revelle BM, Scott D, Beck PJ. Single amino acid
residues in the E- and P-selectin epidermal growth
factor domains can determine carbohydrate binding
specificity. J Biol Chem. 1996; 271(11): 16160-16170.
18. Alexiou D, Karayiannakis AJ, Syrigos KN, Zbar A,
Sekara E, Michail P, et al. Clinical significance of
serum levels of E-selectin, intercellular adhesion
molecule-1, and vascular cell adhesion molecule-1
in gastric cancer patients. Am J Gastroenterol. 2003;
98(2): 478-485. 19. Reference SNP (refSNP) Cluster Report: rs5361.
Available from: http://www.ncbi.nlm.nih.gov/projects/
SNP/snp_ref.cgi?rs=5361.
20. Rao RM, Clarke JL, Ortlepp S, Robinson MK, Landis
RC, Haskard DO. The S128R polymorphism of Eselectin
mediates neuraminidase-resistant tethering
of myeloid cells under shear flow. Eur J Immunol.
2002; 32(1): 251-260.
21. Rao RM, Haskard DO, Landis RC. Enhanced recruitment
of Th2 and CLA-negative lymphocytes by
the S128R polymorphism of E-selectin. J Immunol.
2002; 169(10): 5860-5865.
22. Wenzel K, Hanke R, Speer A. Polymorphism in the
human E-selectin gene detected by PCR-SSCP. Hum
Genet. 1994; 94(4): 452-453.
23. Cheng DY, Hao YW, Zhou WL, Ma YR. E-selectin
S128R polymorphism is associated with cancer risk:
A meta-analysis. Asian Pac J Cancer Prev. 2014;
15(7): 3247-3252.
24. NCCN Guideline. Genetic/Familial High-Risk
Assessment: Breast and Ovarian Version 1, 2018.
Professional version available from (subscription
needed): https://www.nccn.org/professionals/physician_
gls/pdf/ genetics_screening.pdf.
25. Xia HZ, Du WD, Wu Q, Chen G, Zhou Y, Tang XF,
et al. E-selectin rs5361 and FCGR2A rs1801274 variants
were associated with increased risk of gastric
cancer in a Chinese population. Mol Carcinog. 2012;
51(8): 597-607.
26. L iarmakopoulos E, Gazouli M, Aravantinos G, Theodoropoulos
G, Rizos S, Vaiopoulou A, et al. E-Selectin
S128R gene polymorphism in gastric cancer.
Int J Biol Markers. 2013; 28(1): 38-42.
27. Hebbar M, Adenis A, Revillion F, Duhamel A, Romano
O, Truant S, et al. E-selectin gene S128R
polymorphism is associated with poor prognosis in
patients with stage II or III colorectal cancer. Eur J
Cancer. 2009; 45(10): 1871-1876.
28. Panoussopoulos GS, Theodoropoulos G, Michalopoulos
NV, Gazouli M, Flessas J, Taka S, et al.
Analysis of E-Selectin S128R gene polymorphism
in pancreatic cancer. J Surg Oncol. 2010; 102(6):
604-607.
29. Kontogianni P, Zambirinis CP, Theodoropoulos G,
Gazouli M, Michalopoulos NV, Flessas J, et al. The
impact of the stromal cell-derived factor-1-3’A and
E-selectin S128R polymorphisms on breast cancer.
Mol Biol Rep. 2013; 40(1): 43-50.
30. Naidu R, Har YC, Taib NA. Polymorphic variant
Ser128Arg of E-Selectin is associated with breast
cancer risk and high grade tumors. Onkologie. 2011;
34(11): 592-597.
|
|
|
|



 |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|
|